Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis by Sampaio, Elizabeth P. et al.
Signal transducer and activator of transcription 1 (STAT1) gain-
of-function mutations and disseminated coccidioidomycosis
and histoplasmosis
Elizabeth P. Sampaio, MD, PhDa,b, Amy P. Hsu, BAa, Joseph Pechacek, BAa, Hannelore I.
Bax, MDa,c, Dalton L. Dias, BAa, Michelle L. Paulson, MDd, Prabha Chandrasekaran, PhDa,
Lindsey B. Rosen, BSa, Daniel S. Carvalho, PhDa,b, Li Ding, MDa, Donald C. Vinh, MDe,
Sarah K. Browne, MDa, Shrimati Datta, PhDf, Joshua D. Milner, MDf, Douglas B. Kuhns,
PhDg, Debra A. Long Priel, BSg, Mohammed A. Sadat, MDh, Michael Shiloh, MD, PhDi,
Brendan De Marco, MDi, Michael Alvares, MDj, Jason W. Gillman, MDi, Vivek Ramarathnam,
MDi, Maite de la Morena, MDj, Liliana Bezrodnik, MDk, Ileana Moreira, MDk, Gulbu Uzel,
MDa, Daniel Johnson, MDl, Christine Spalding, RNa, Christa S. Zerbe, MDa, Henry Wiley,
MDm, David E. Greenberg, MDi, Susan E. Hoover, MD, PhDn, Sergio D. Rosenzweig, MD,
PhDh,o, John N. Galgiani, MDn, and Steven M. Holland, MDa
athe Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, Laboratory of Host
Defenses, National Institutes of Health (NIH), Bethesda
bthe Leprosy Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro
cthe Department of Internal Medicine and Department of Medical Microbiology and Infectious
Diseases, Erasmus Medical Center, Rotterdam
dthe Clinical Research Directorate/CMRP SAIC-Frederick, NCI-Frederick, Frederick
ethe Division of Infectious Diseases, McGill University Health Centre, Montreal
fthe Allergic Inflammation Unit, Laboratory of Allergic Diseases Laboratory of Host Defenses,
National Institutes of Health (NIH), Bethesda
gthe Clinical Services Program, SAIC-Frederick, NCI-Frederick, Frederick
hthe Infectious Diseases Susceptibility Unit, Laboratory of Host Defenses, National Institutes of
Health (NIH), Bethesda
ithe Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas
jthe Division of Allergy and Immunology, University of Texas Southwestern Medical Center,
Dallas
kthe Immunology Unit, Pediatric Hospital R. Gutierrez, Buenos Aires
lComer Children's Hospital, University of Chicago
mthe Clinical Trials Branch, National Eye Institute, NIH, Bethesda,University of Arizona College of
Medicine, Tucson
Corresponding author: Steven M. Holland, MD, CRC B3-4141 MSC 1684, Bethesda, MD 20892-1684. h@nih.gov.
Disclosure of potential conflict of interest: D. C. Vinh has received research support from the Canadian Institutes of Health Research
Post-doctoral Fellowship, CSL Behring Canada, and Astellas Canada; has consultant arrangements with CSL Behring Canada and
Pfizer Canada; and has received payment for lectures from CSL Behring Canada and Sunovion/Sepracor. D. B. Kuhns and D. A. Long
Priel have received grants from the National Cancer Institute/National Institutes of Health. V. Ramarathnam is employed by Private
Practice ID. S. D. Rosenzweig receives royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts
of interest.
NIH Public Access
Author Manuscript
J Allergy Clin Immunol. Author manuscript; available in PMC 2014 June 01.
Published in final edited form as:
J Allergy Clin Immunol. 2013 June ; 131(6): 1624–1634. doi:10.1016/j.jaci.2013.01.052.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
nValley Fever Center for Excellence, University of Arizona College of Medicine, Tucson
othe Primary Immunodeficiency Clinic, National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health (NIH), Bethesda
Abstract
Background—Impaired signaling in the IFN-γ/IL-12 pathway causes susceptibility to severe
disseminated infections with mycobacteria and dimorphic yeasts. Dominant gain-of-function
mutations in signal transducer and activator of transcription 1 (STAT1) have been associated with
chronic mucocutaneous candidiasis.
Objective—We sought to identify the molecular defect in patients with disseminated dimorphic
yeast infections.
Methods—PBMCs, EBV-transformed B cells, and transfected U3A cell lines were studied for
IFN-γ/IL-12 pathway function. STAT1 was sequenced in probands and available relatives.
Interferon-induced STAT1 phosphorylation, transcriptional responses, protein-protein interactions,
target gene activation, and function were investigated.
Results—We identified 5 patients with disseminated Coccidioides immitis or Histoplasma
capsulatum with heterozygous missense mutations in the STAT1 coiled-coil or DNA-binding
domains. These are dominant gain-of-function mutations causing enhanced STAT1
phosphorylation, delayed dephosphorylation, enhanced DNA binding and transactivation, and
enhanced interaction with protein inhibitor of activated STAT1. The mutations caused enhanced
IFN-γ–induced gene expression, but we found impaired responses to IFN-γ restimulation.
Conclusion—Gain-of-function mutations in STAT1 predispose to invasive, severe,
disseminated dimorphic yeast infections, likely through aberrant regulation of IFN-γ–mediated
inflammation.
Keywords
Signal transducer and activator of transcription 1; IFN-γ; progressive multifocal
leukoencephalopathy; Histoplasma capsulatum; Coccidioides immitis; thrush
The IFN-γ/IL-12 signaling pathway controls extrapulmonary infections with bacteria, such
as nontuberculous mycobacteria, BCG, Mycobacterium tuberculosis, and Salmonella
species,1,2 as well as the dimorphic fungi Histoplasma capsulatum,3 Paracoccidioides
brasiliensis,4 and Coccidioides immitis.5,6 Stimulation of IFN-γ and IFN-α receptors leads
to phosphorylation of signal transducer and activator of transcription 1 (STAT1), which
homodimerizes and heterodimerizes before translocating to the nucleus, where interferon-
induced genes are activated.7 Complete recessive mutations in STAT1 cause susceptibility
to viral, mycobacterial, and bacterial infections, whereas heterozygous inhibitory STAT1
mutations cause mild disseminated BCG or nontuberculous mycobacterial infections.8-10
Recently, dominant gain-of-function mutations in STAT1 were described as causing chronic
mucocutaneous candidiasis (CMC), impaired STAT1 dephosphorylation, and diminished
numbers of IL-17–producing T cells.11,12
The regulation of STAT1 activity includes the suppressor of cytokine signaling and protein
inhibitor of activated STAT (PIAS) families of proteins.13,14 Posttranslational modifications
of STATs (acetylation, methylation, SUMOylation, and ISG15ylation among others) also
regulate their function and response. PIAS1 is thought to interfere with STAT1 DNA
binding and to recruit other transcriptional coregulators. PIAS proteins have also been
shown to have E3 ligase activity and to promote protein SUMOylation.15
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We identified 5 patients with disseminated dimorphic fungal infections who had mutationsin
STAT1: 2 patients had disseminated refractory coccidioidomycosis beginning in childhood
or adolescence without CMC, and 3 patients had disseminated histoplasmosis and CMC,
including 1 patient who also had progressive multifocal leukoencephalopathy (PML). These
are gain-of-function mutations that ultimately lead to delayed dephosphorylation of STAT1,
lower STAT1 methylation, enhanced STAT1/PIAS1 association, and an impaired response
to IFN-γ restimulation.
Methods
Patients and blood samples
All samples were collected under approved National Institutes of Health (NIH) protocols; all
patients or their parents provided written informed consent. Healthy volunteer blood
samples were obtained under approved protocols through the Department of Transfusion
Medicine, NIH.
Cell lines
EBV-transformed B-cell lines derived from patients and healthy donors were maintained in
RPMI 1640 with 20% FCS, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 μg/mL
streptomycin at 37°C in a humidified 5% CO2 incubator. STAT1-deficient U3A cells
(generously provided by G. Stark, Cleveland Clinic, Cleveland, Ohio) were maintained in
complete Dulbecco modified Eagle medium (see the Methods section in this article's Online
Repository at www.jacionline.org).
STAT1 sequencing
Genomic DNA (PureGene Gentra DNA isolation kit; Qiagen, Hilden, Germany) and total
RNA (STAT-60 RNA isolation kit; Tel-Test, Friendswood, Tex) were extracted from EBV-
transformed B-cell lines or polymorphonuclear leukocytes. Primers spanning exons and
flanking splice sites of human genomic STAT1 and full-length cDNA were designed with
Primer Select (Lasergene; DNASTAR, Madison, Wis). Genomic amplification was
performed with Platinum PCR Supermix High Fidelity (Invitrogen, Carlsbad, Calif).
Samples were treated with ExoSAP (Affymetrix, Santa Clara, Calif), and 1 μL of the
resulting product was used in sequencing reactions with Big Dye Terminators v3.1 (Applied
Biosystems, Foster City, Calif), purified with Performa DTR short-well plate kit (Edge
BioSystems, Gaithersburg, Md), and run on an Applied Biosystems 3730XL sequencer.
Alignment was to the consensus sequence NM_007315.3 using Sequencer software (Gene
Codes, Ann Arbor, Mich).
Constructs
Mutated STAT1 sequences or green fluorescent protein (GFP)–tagged constructs were
created with a STAT1 expression vector (BioInnovatise, Rockville, Md). Wild-type (WT)
and mutant STAT1 plasmids were isolated with the QIAprep Miniprep Kit (Qiagen),
according to the manufacturer's recommendations, and all mutations were verified by means
of sequencing. Transient transfection of U3A cells was done with the Nucleofactor Amaxa
device (Lonza, Walkersville, Md), according to the manufacturer's recommendations.
Reporter gene assay
U3A cells were cotransfected with WT and/or mutant STAT1 expression constructs along
with a plasmid containing tandem interferon-response elements (gamma-activated sequence
[GAS] and type I interferon response element [ISRE]) driving a luciferase reporter gene (1
μg; Panomics, Fremont, Calif). A Renilla expression vector was cotransfected to measure
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transfection efficiency. Cells were stimulated with human IFN-γ or IFN-α2b at 1000 IU/mL
for 6 hours. Luciferase activity was evaluated with a dual luciferase assay (Promega,
Madison, Wis; see the Methods section in this article's Online Repository). Data are
expressed as the fold increase in response to interferon over the WT unstimulated samples.
Evaluation of STAT1 activation
Phosphorylated STAT1 (pSTAT1) was assayed in U3A and EBV-B cells stimulated with
IFN-γ (400 IU/mL) or IFN-α (1,000 IU/mL). For evaluation of dephosphorylation, pSTAT1
kinetics were assayed in cells stimulated with IFN-γ from 30 to 120 minutes. Cell lysates
were recovered and analyzed by means of Western blotting (WB) and flow cytometry. For
immunoprecipitation, cell lysates were incubated with anti-STAT1 antibody and protein G–
Sepharose (Amersham Biosciences, Piscataway, NJ) overnight at 4°C, and immunoreactive
proteins were resolved by means of WB.
Downregulation of PIAS1
High-purity small interfering RNA (siRNA) oligonucleotides that target PIAS1 and a control
siRNA were obtained from Darmacon (Thermo Scientific, Lafayette, Colo). U3A cells were
transiently transfected with the siRNA (ON-TARGETplus SMARTpool siRNA, 50 nmol/L)
through eletroporation (Nucleofactor Amaxa), cotransfected with WT or mutant STAT1
constructs, and stimulated with IFN-γ (400 IU/mL).
Real-time PCR
Total RNA was extracted from cultured cells (PBMCs isolated from venous blood by means
of density centrifugation and transfected U3A cells) with the RNeasy Mini Kit (Qiagen). For
real-time PCR, 1 μg of total RNA was reverse transcribed (Invitrogen), and the resulting
cDNA was amplified by means of PCR with the ABI 7500 Sequencer and TaqMan
expression assays (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase was
used as a normalization control. The data were analyzed with the 2−ΔΔCT method, and
results were expressed as mean fold induction.
Statistical analysis
Results are reported as means ± SDs, unless otherwise stated. Differences between groups
were assessed by using the Student t test (GraphPad Prism; GraphPad Software, San Diego,
Calif). The statistical significance level adopted was a P value of less than .05.
Results
Patient 1 is a Hispanic female native of Arizona with no relevant previous or family history
who presented at 14 years of age with extensive persistent tinea capitis and kerion caused by
Trichophyton tonsurans. At age 17 years, she had prolonged cough, a painless right neck
mass, fatigue, and weight loss. Computed tomography (CT) demonstrated multiple nodules
throughout both lungs. CT confirmed diffuse progression with new osteomyelitis at
vertebral bodies C6 through T5 and multiple lesions throughout the liver and spleen. She
received liposomal amphotericin B (L-AmB) and voriconazole and then posaconazole. At
age 20 years, a new Coccidioides species–induced skin lesion developed that was associated
with anorexia and weight loss. Magnetic resonance imaging (MRI) demonstrated
progressive disease throughout (Fig 1, A), including a new intramedullary spinal cord lesion
at T9 with cord edema (Fig 1, B).
Patient 2 is a white girl native to Arizona who presented at age 9½ years with 3 weeks of
nightly fevers and cough. She had multiple pulmonary nodules, massive necrotic
intrathoracic lymphadenopathy with compression of the right mainstem bronchus and
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vasculature, and lesions of the manubrium and L4, L5, T8, and T9 vertebrae.
Coccidioidomycosis was diagnosed by means of serology, leading to fluconazole therapy.
Fluconazole was changed to itraconazole, but the pulmonary and intrathoracic lesions
continued to enlarge (see Fig E1 and the Results section in this article's Online Repository at
www.jacionline.org). At age 13½ years, multiple ring-enhancing lesions appeared in both
cerebral hemispheres and the cerebellum. A right subretinal mass thought to be coccidioidal
was treated with intraocular amphotericin B without improvement. Despite aggressive
treatment with caspofungin, voriconazole, posaconazole, and steroids for inflammatory
control, she died of overwhelming Coccidioides species infection at 17 years.
Patient 3 is a 21-year-old white man with a lifetime history of recurrent infections; 6
fractures in childhood, including the long and short bones; muscle weakness and atrophy;
and bronchiectasis. Thrush appeared at 7 days of life and persisted for 4 years despite topical
antifungal therapies. He also had onychomycosis. Fluconazole was started at age 4 years,
and fungal infections resolved. At the same age, a single cervical node involved with
Mycobacterium fortuitum was surgically excised. At age 12 years, he had severe
disseminated histoplasmosis, which responded to itraconazole. Since age 15 years, he has
had progressive bilateral upper limb muscle atrophy and weakness of unclear cause.
Patient 4 is a 31-year-old man who presented with disseminated histoplasmosis at age 17
years. He had tympanostomy tubes placed as a child without subsequent ear infections. He
often had oral sores, and at age 16 years, he was hospitalized for oral candidiasis with
probable esophageal involvement. At age 17 years, he had lymphadenopathy, fever, and
weight loss caused by histoplasmosis involving the liver, bone marrow, and lymph nodes. At
age 30 years, headaches and ataxia led to the discovery of multiple brain lesions.
Craniotomy and biopsy confirmed the largest lesion to be Histoplasma capsulatum. At age
31 years, brain biopsy demonstrated PML caused by JC virus detected on
immunohistochemistry. During treatment with IL-2, he had Pseudomonas aeruginosa-
induced sepsis and died.
Patient 5 is a 25-year-old woman born to unrelated parents who had disseminated
histoplasmosis at age 7 years characterized by fever, hepatosplenomegaly,
lymphadenopathy, and dyspnea. H capsulatum on lymph node and lung biopsies was
successfully treated with itraconazole. At age 8 years, histoplasmosis in sputum associated
with dyspnea and lymphadenopathy was successfully retreated with itraconazole. After
completion of treatment, she had recurrent oral, cutaneous, and vaginal candidiasis. Neither
her siblings nor her parents have fungal infections or autoimmunity.
STAT1 mutations
Full-length sequencing of STAT1 genomic and complementary DNA identified STAT1
heterozygous mutations in each patient. Patient 1 had c.1057G>A, E353K in the DNA-
binding domain; patient 2 had c.800C>T, A267V in the coiled-coiled domain11,12; patient 3
had c.1154C>T, T385M in the DNA-binding domain; and patient 4 had c.820C>G, R274G
and patient 5 had c.514T>C, F172L, both of which were in the coiled-coil domain (Fig 2,
A). R274G is a different amino acid change at the same location as one previously reported
in patients with CMC.12 In all cases sequencing of full-length cDNA demonstrated equal
representation of mutant and WT alleles, indicating stability of the mutant mRNA. None of
the patients' parents (patient 4's parents were not tested) carried the identified mutations, nor
were these mutations found in dbSNP 132 or the 1000 Genomes Project.
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Delayed STAT1 dephosphorylation, enhanced DNA binding, and transactivation
STAT1-deficient U3A cells were transfected with WT and mutant STAT1 alleles to evaluate
the activity of the STAT1 mutant proteins. Immunoblotting confirmed equal expression in
transfected cells (Fig 2, B).
The STAT1 mutants in patients with histoplasmosis and coccidioidomycosis, as well as
F172L (a critical site for STAT1 dephosphorylation),16 showed enhanced IFN-γ– and IFN-
α–induced STAT1 phosphorylation in EBV-B cells (patients 1, 2, and 3: E353K, A267V,
and T385M, respectively) and transfected U3As (R274G and F172L) compared with WT
cells (see Fig E2, A, in this article's Online Repository at www.jacionline.org). Confocal
microscopy (see the Results section in this article's Online Repository at
www.jacionline.org) confirmed the ability of STAT1 mutants to translocate to the nucleus
after activation (Fig E2, B). These gain-of-function mutations led to persistent STAT1
phosphorylation for up to 120 minutes, a time at which healthy subjects had almost
completely returned to baseline levels (Fig 3, A). Experiments with the kinase inhibitor
staurosporine (see Fig E2, C) and flow cytometry confirmed the impaired dephosphorylation
of the mutant proteins (Fig 3, B).
STAT1 GAS-binding activity in stimulated EBV-B cells from patients with gain-of-function
mutants but not the dominant negative mutant L706S was enhanced in response to
interferons when compared with that seen in healthy subjects (see Fig E3, A, in this article's
Online Repository at www.jacionline.org). Assessment of transactivation response in U3A
cells transfected with mutant constructs also showed enhanced activation of the GAS-
luciferase reporter after IFN-γ and IFN-α stimulation compared with WT cells (Fig 3, C).
When WT STAT1 was cotransfected with the mutants, the enhanced activity remained
essentially unchanged, confirming the dominant gain of function exerted by the mutant
alleles (Fig 3, C). Interestingly, cotransfection of U3A cells with these STAT1 mutants
along with the L706S dominant negative STAT1 construct showed the gain-of-function
mutants to overcome the dominant negative mutant (Fig 3, D). The IFN-α–induced
transcription activity in cells cotransfected with a dependent type I interferon response
element (ISRE) was not different than that observed for the WT cells (see Fig E3, B).
PIAS1-STAT1 interaction
PIAS1 modulates STAT1 activity, and STAT1/PIAS1 interaction is also reported to be
modulated by methylation of STAT1.17,18 After stimulation with interferons, PIAS1/STAT1
interaction was enhanced in patients' B cells compared with healthy donors when cell lysates
were immunoprecipitated for STAT1 and blotted for associated PIAS1 (Fig 4, A).
Moreover, immunoprecipitated lysates immunoblotted with a mono/dimethylarginine
antibody (DMA) showed diminished methyl-STAT1 in stimulated mutant transfected U3A
or EBV-B cells compared with normal cells (see Fig E4, A, in this article's Online
Repository at www.jacionline.org). Treatment of cells with the well-characterized methyl
donor S-adenosylmethionine (SAMe; 1600 nmol/L; Sigma-Aldrich, St Louis, Mo), which
donates to the terminal nitrogen of arginine residues on target proteins,19 led to enhanced
methyl-associated STAT1 (see Fig E4, B), decreased STAT1/PIAS1 association (Fig 4, B),
and reduced IFN-γ–induced STAT1 phosphorylation compared with that seen in untreated
cells (see Fig E4, C).
Gene expression
The effects of these novel dominant STAT1 mutations on IFN- gamma;–inducible target
genes (CXC chemokine ligand 9 [CXCL9] and CXCL10[IP10], see Fig E5, A, in this
article's Online Repository at www.jacionline.org) but not on traditional IFN-α target genes
(MX1 and ISG15, see Fig E5, B) were enhanced in U3A cells carrying mutant STAT1
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constructs compared with WT STAT1. To better understand the connection of STAT1
hyperactivation and impaired response in the IFN-γ axis, we examined whether the
hyperresponsiveness induced by these mutations impaired later IFN-γ responses.
Transfected U3A cells were stimulated with IFN-γ for 3 hours, washed free of IFN-γ (IFN-
γ restimulation), and then restimulated with IFN-γ for an additional 3 hours (IFN-γ/IFN-γ).
In these experiments WT STAT1-expressing cells showed clear-cut ability to augment gene
expression (CXCL9 and CXCL10) after both stimulation and restimulation. In contrast,
mutant STAT1 cells were able to upregulate their response to the initial IFN-γ stimulation
but not restimulation (Fig 5). These results were reproduced when using primary patients'
PBMCs restimulated in vitro (see Fig E5, C). Failure to respond to restimulation with IFN-γ
was also observed for the mutations K286I and T288A, which have been described as being
associated with CMC alone (see Fig E5, D).12
We investigated whether PIAS1 plays a role in the impaired gene expression seen after
restimulation. Knockdown of PIAS1 (see Fig E6 in this article's Online Repository at
www.jacionline.org) in U3A cells (but not control siRNA, data not shown) cotransfected
with gain-of-function STAT1 mutants led to near normalization of gene expression after
restimulation (Fig 6).
Cytokine production and evaluation of TH17 response
Secretion of proinflammatory cytokines (TNF-α and IL-12p70) was upregulated in patients
compared with healthy subjects. The TH17 response assayed in PBMCs
(CD3+CD4+CD45RO+ cells) was low for the patients carrying the mutations A267V,
E353K, and T385M (see Fig E7 in this article's Online Repository at www.jacionline.org)
but not in a patient missing IFN-γ receptor 1 (delIFNGR1) or one with disseminated
coccidioidomycosis without a recognized mutation, suggesting that defective production of
TH17 cells is not necessary for the development of disseminated dimorphic fungal infection.
Discussion
Genetic defects in the IFN-γ/IL-12 pathway have been found in patients with severe
disseminated histoplasmosis and coccidioidomycosis,3-6 indicating that underlying
deficiencies in the same genes that control nontuberculous mycobacteria and Salmonella
species are also involved in the control of intracellular fungal disease, which was the reason
to investigate this pathway in our patients in the first place.
Coccidioidomycosis is endemic in the American Southwest into South America, but most
disease is limited and transient. However, dissemination occurs more often in certain ethnic
groups, most notably African American and Filipino subjects, suggesting underlying genetic
contributions.20,21 Both of our patients with disseminated coccidioidomycosis also had years
of progressive pulmonary involvement without associated lung cavitation. Such chronic
manifestations are so distinctly unusual for patients with coccidioidal infection that it might
be specifically associated with aberrant STAT1 function. H capsulatum occurs worldwide,
typically as a limited disease, but disseminated disease signifies immunodeficiency.22
Extrapulmonary coccidioidomycosis and histoplasmosis have also been described in patients
with hyper-IgE syndrome caused by STAT3 mutations,23,24 even though infections are less
severe.
The mutations we identified in STAT1 were in the coiled-coil and DNA-binding domains
and led to severe fungal infections with or without CMC. Notably, patient 4 also had warts
and PML. Recurrent oral herpes virus infections have been reported in STAT1 gain-of-
function mutations,25 as well as severe herpes simplex virus and varicella zoster virus
infections (Uzel et al, accompanying submission). The occurrence of viral, mycobacterial,
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and dimorphic fungal infections with these mutations in STAT1 suggests a functional
overlap of the gain- and loss-of-function mutations, which can converge on the integrity of
secondary responses to IFN-γ.
Members of the PIAS family negatively regulate the Janus kinase–STAT pathway and
modulate nuclear factor κB signaling and other pathways.26,27 PIAS1 interacts with the
amino terminal domain of STAT1 (amino acids 1-191),28 where arginine 31 is located, the
described site for STAT1 and STAT3 methylation.17,29,30 PIAS can also act as a SUMO E3
ligase, which might be relevant because STAT1 SUMOylation seems to modulate the
transcriptional activity of target genes, the expression of PIAS1-sensitive genes, and the
extent of responsiveness to IFN-γ.31 Chromatin immune precipitation studies on PIAS1-
deficient macrophages and transcriptional analysis of cells treated with interferon found
increased STAT1 binding to the promoters of PIAS1-sensitive genes (CXCL9 and CXCL10)
but not PIAS1-insensitive genes, indicating a select population of genes regulated by
PIAS1.27,32 Analogously, lysine methylation modifies STAT3-mediated responses.33
Disruption of K140 caused persistent STAT3 phosphorylation, differentially modulated
IL-6–induced gene expression, and downregulation of a subset of genes after restimulation.
Similarly, the STAT1 mutations we identified did not normally upregulate gene expression
after restimulation. Moreover, reduction of PIAS1 in the mutant cells restored the
restimulation response to IFN-γ, as observed in WT cells. It is noteworthy that the defect is
brought out predominantly by restimulation, suggesting that the occurrence of IFN-γ
tachyphylaxis might be central to the defect in this condition.
STAT1/PIAS1 association can be modulated by STAT1 methylation.17,18,34,35 Treatment of
patients' cells with SAMe reduced STAT1/PIAS1 association and decreased STAT1
phosphorylation and restored the restimulation response to IFN-γ in vitro. SAMe is a
principal biologic methyl donor, the precursor for polyamine biosynthesis, described to
overcome hepatitis virus–associated STAT1 hypomethylation.19,34-36 SAMe might have
potential therapeutic uses in patients with STAT1 mutants.
STAT1 has a critical role in the control of fungal and other infections. Human susceptibility
to coccidioidomycosis and histoplasmosis is apparently enhanced by both loss- and gain-of-
function mutations in the IFN-γ/IL-12 pathway, likely through mechanisms other than the
impaired IL-17 response that predisposes patients to CMC.
Supplementary Material
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CMC Chronic mucocutaneous candidiasis
CSF Cerebrospinal fluid
CT Computed tomography
DMA Mono/dimethylarginine antibody
GAS0 Gamma-activated sequence
GFP Green fluorescent protein
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ISRE Type I interferon response element
L-AmB Liposomal amphotericin B
MRI Magnetic resonance imaging
NIH National Institutes of Health
PIAS Protein inhibitor of activated STAT
PML Progressive multifocal leukoencephalopathy
pSTAT1 Phosphorylated STAT1
SAMe S-adenosylmethionine
siRNA Small interfering RNA
STAT1 Signal transducer and activator of transcription 1
WB Western blotting
WT Wild-type
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Clinical implications
STAT1 gain-of-function mutations predispose to disseminated dimorphic fungal
infections. Prolonged STAT1 phosphorylation, hypomethylation, and impaired
dephosphorylation impair IFN-γ restimulation, leading to apparent tachyphylaxis.
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Fig 1.
Patient 1. A, Extensive right upper lung, mediastinal, and pleural involvement with C
immitis. B, MRI showing an intramedullary spinal cord lesion (arrow) with edema and cord
compression.
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Fig 2.
STAT1 mutants. A, STAT1 coding region. TAD, Transactivation domain. Mutations were
associated with (blue arrows) disseminated coccidioidomycosis and (green arrows)
disseminated histoplasmosis. L706S was the dominant negative mutation. B, U3A cells
transfected with STAT1 mutants, WT or empty vector, and WB with anti-STAT1 and anti-
tubulin antibodies.
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Fig 3.
STAT1 mutants lead to delayed dephosphorylation and enhanced luciferase GAS-induced
activity. A, Dephosphorylation in EBV-B cells from patients and control subjects (Nm)
stimulated with IFN-γ for the indicated periods. B, Dephosphorylation assayed by means of
flow cytometry in U3A cells. Results are representative of at least 3 independent
experiments. MFI, Mean fluorescence intensity; NS, nonstimulated. C, Transcriptional
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responses to IFN-γ and IFN-α in U3A cells transfected with STAT1 mutant constructs and
when cotransfected with WT STAT1. D, U3A cells transfected with L706S showed no
negative effect on the mutants A267V and E353K. Data show the mean fold increase
relative to the WT nonstimulated specimens from a total of 5 experiments. *P < .05 when
compared with stimulated WT, respectively. **P < .01 compared with L706S.
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Fig 4.
Increased STAT1/PIAS1 association. A, After interferon stimulation, cell lysates from EBV-
B cells of patients and control subjects (Nm) were IP:WB anti-STAT1: anti-PIAS1 antibody.
B, EBV-B cells treated with SAMe were evaluated as above. Blots are representative of 3
independent experiments for each condition. Numbers are band densities normalized to the
nonstimulated samples (NS).
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Fig 5.
Gene expression: restimulation experiments in transfected U3A cells. Cells were stimulated
or not (NS) with IFN-γ, washed, and restimulated (IFN-γ/IFN-γ) or not (IFN-γ rest).
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Expression of IFN-γ (CXCL9 [A] and CXCL10 [B]) target genes was evaluated. Results are
means ± SDs of 3 independent experiments. *P < .05 compared with IFN-γ rest.
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Fig 6.
Reduction of PIAS1 modulates the IFN-γ–induced gene response. Evaluation of gene
expression in U3A cells cotransfected with WT or mutant STAT1 and with siRNA directed
against PIAS1. Cells were treated as described in Fig5. Restimulated cells =IFN-γ/IFN-γ or
PIAS siRNA IFN-γ/IFN-γ. Results are means ± SDs of 3 independent experiments. NS,
Nonstimulated. *P < .05 when compared with IFN-γ rest. A, WT and E353K with and
without PIAS siRNA. B, WT, A267V, and R274G with and without PIAS siRNA.
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